Search research articles
Contact Us
Filters
Showing results (241-250 of 299) with videos related to
Page
of 30
Sort By:
Cancer
|
April 23, 2013
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study
Jeffrey R Infante, Tony R Reid, Allen L Cohn, et al.
Nature Medicine
|
June 8, 2019
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Ryan J Sullivan, Omid Hamid, Rene Gonzalez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 15, 2016
A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors
Anthony W Tolcher, Johanna C Bendell, Kyriakos P Papadopoulos, et al.
Cancer Medicine
|
January 10, 2014
Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer
Andres Forero-Torres, Jeffrey R Infante, David Waterhouse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 19, 2011
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies
Glen J Weiss, Jeffrey R Infante, E Gabriela Chiorean, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 3, 2017
Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors
Howard A Burris, Jeffrey R Infante, Stephen M Ansell, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
September 18, 2013
Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist
Harvey Wong, Stephen E Gould, Nageshwar Budha, et al.
The Lancet. Oncology
|
December 9, 2017
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Manish R Patel, John Ellerton, Jeffrey R Infante, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2020
Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
Ani S Balmanoukian, Jeffrey R Infante, Raid Aljumaily, et al.
Investigational New Drugs
|
July 25, 2016
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
J E Grilley-Olson, P L Bedard, A Fasolo, et al.
Page
of 30
Search research articles
Search
Showing results (241-250 of 299) with videos related to
Sort By:
Page
of 30
Cancer
|
April 23, 2013
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study
Jeffrey R Infante, Tony R Reid, Allen L Cohn, et al.
Nature Medicine
|
June 8, 2019
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Ryan J Sullivan, Omid Hamid, Rene Gonzalez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 15, 2016
A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors
Anthony W Tolcher, Johanna C Bendell, Kyriakos P Papadopoulos, et al.
Cancer Medicine
|
January 10, 2014
Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer
Andres Forero-Torres, Jeffrey R Infante, David Waterhouse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 19, 2011
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies
Glen J Weiss, Jeffrey R Infante, E Gabriela Chiorean, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 3, 2017
Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors
Howard A Burris, Jeffrey R Infante, Stephen M Ansell, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
September 18, 2013
Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist
Harvey Wong, Stephen E Gould, Nageshwar Budha, et al.
The Lancet. Oncology
|
December 9, 2017
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Manish R Patel, John Ellerton, Jeffrey R Infante, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2020
Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
Ani S Balmanoukian, Jeffrey R Infante, Raid Aljumaily, et al.
Investigational New Drugs
|
July 25, 2016
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
J E Grilley-Olson, P L Bedard, A Fasolo, et al.
Page
of 30